• Infobird has continually invested significant resources in R&D to support its existing business, enhance its service and product offerings, incubate new technological breakthroughs and business initiatives, and maintain its technological advantages
• IFBD acknowledges that it is through innovation and continuous R&D that it has added advanced functionalities to its products
• The company believes that its R&D capabilities, along with its comprehensive service and product portfolio, diverse sales and marketing network, and experienced management team, position it favorably in the competitive SaaS customer engagement industry in China

Infobird (NASDAQ: IFBD), a software-as-a-Service (“SaaS”) in China, providing AI-enabled end-to-end customer engagement and sales force management solutions, believes it is well-positioned to compete in the expanding SaaS customer engagement industry in China, thanks, in part, to its research and development (“R&D”) capabilities and proprietary technologies.

In its annual report filed with the SEC as form 20-F (https://ibn.fm/E6khV), for example, IFBD notes: “We invest significant resources in R&D – not only to support our existing business and enhance our service and product offerings – but also to incubate new technological breakthroughs and business initiatives… We have invested significant resources to maintain our technological advantages and intend to continue to extensively invest in our R&D capabilities.”

Infobird further acknowledges that it is through years of R&D that it has included advanced functions on some of its products and services, such as its AI Chatbots, which can now “analyze real-time conversation, understand conversation context and flows, and proactively recommend products and services.”

The AI voice chatbot and AI text chatbot software is one of four software offerings that are currently part of the company’s customer engagement solutions. The others are: cloud call center, intelligent telemarketing, and intelligent omnichannel customer service. IFBD leverages its proprietary cloud-native architecture, no-code development platform, patented VoIP technologies, and AI and machine learning capabilities to offer these software solutions, which help its corporate clients manage and deliver end-to-end customer engagement activities throughout the various stages of the sales process.

For instance, the cloud call center software enables clients to access their accounts and take inbound or outbound calls through applications installed on various devices. Its intelligent telemarketing software initiates follow-up calls with sales leads utilizing the company’s cloud call center. It can also be integrated with other software offerings, including the AI voice chatbot, to provide additional functionalities.

Regarding its AI-enabled sales force management software, the company acknowledges that AI has proven beneficial to its clients by eliminating the low efficiency associated with manual quality inspection (https://ibn.fm/6jcuB).

AI, the company says, has birthed intelligent quality inspection, doing away with the resource-intensive customer service quality inspection previously carried out by human inspectors. The manual sampling that was synonymous with the traditional customer service management used to have low efficiency, untimeliness, and narrow coverage and lacked objectivity. These factors ultimately made it difficult for management to meet its needs. However, with Infobird’s AI-driven sales force management solutions, the narrative has changed.

Its more comprehensive, automatic intelligent quality inspection is faster, saves 90% of resources that businesses would have otherwise used to hire quality inspection personnel, and enables managers to deal with potential risks by notifying them of any anomaly beforehand.

These products incorporate IFBD’s proprietary technologies, including its patented VoIP and other internet technologies and software copyrights. The company currently has 70 intellectual property rights, comprising 19 patents and 51 software copyrights.

In the ever-expanding but highly fragmented SaaS customer engagement industry in China, Infobird has set sights on claiming the lion’s share of the market. It intends to do this by leveraging its comprehensive service and product portfolio, diverse sales and marketing network, an experienced management team, and R&D capabilities, having already launched the next generation of SaaS in the country.

For more information, visit the company’s website at www.Infobird.com/en/index.html.

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

About ChineseWire

ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.

For more information, please visit https://www.ChineseWire.com

Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer

ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com

ChineseWire is part of the InvestorBrandNetwork.

Electric vehicles (“EVs”) are poised to replace conventional gas-powered vehicles gradually over the next couple of decades. By discarding the century-old internal combustion engine in exchange for lithium-ion batteries and electric motors, several countries, including the United States, hope to cut down on their carbon emissions. However, a recent report commissioned by the Pentagon says that zero-emission electric cars may not be feasible for the U.S. Army, potentially locking the industry out of a market that spends big on new technologies.

Titled “Powering the US Army of the Future,” the report by the National Academies of Sciences, Engineering, and Medicine analyzed the future energy requirements of manned and unmanned vehicles and dismounted soldiers on multi-domain battlefields through 2035. Specifically, it centered on the energy needs of an armored brigade combat team that uses a combination of light vehicles, tactical vehicles and distributed soldiers. The authors of the report recommended that the army diversify the fuels it uses to run its ground vehicles but warned that battery electric vehicles and electricity are not practical.

Since the late 1970s, the Army has used JP-8, a kerosene-based jet fuel that is also used in generators, similar equipment and aircraft. Although this fuel was introduced as a replacement to diesel in an effort to standardize liquid fuel use and take advantage of economies of scale, it is not available in theater and has to be transported in times of war. During Operation Desert Storm, for instance, there was plenty of liquid fuel around locally, but the army couldn’t use it.

Committee co-chair John Koszewnik, a retired chief technical officer for Achates Power and an internal combustion engine expert, recommends using diesel fuel during wartime as well. Not only is it more energy dense, but it can also be sourced locally. By using biofuels, diesel and diesel-based fuels, the Army can shorten supply lines, make the U.S. less vulnerable and reduce supply timelines. The committee also looked at compressed and liquified hydrogen but found that these alternatives would require a significant increase in trucks to deliver the same amount of energy as diesel.

Other alternative fuels considered were synthetic aviation fuel and B100 biodiesel, but the ground vehicles would require minor modifications for those solutions to be viable. Another alternative was an unmanned JP-8/diesek powered hybrid that would run on a solid oxide fuel cell. Although ICE vehicles have it beat in terms of distribution and energy density, this particular vehicle offers benefits such as silent stealth and does away with the need for carrying heavy batteries.

Electricity and electric vehicles, on the other hand, don’t seem to be as viable. One major problem would be transporting enough electricity to the battlefield to charge ground vehicles as fast as possible. A concept for an advanced mobile microreactor dubbed “Project Pele,” for instance, wouldn’t be able to recharge a single Abrams tank in one go, requiring multiple mobile nuclear reactors to do the job. Other issues the Army would have to deal with were it to go electric include battery energy density and the safety of combat EVs.

While some resistance is to be expected from institutions that have relied on fossil fuel since their creation, the push to vehicular electrification being championed by entities such as Ideanomics Inc. (NASDAQ: IDEX) is likely to gain momentum as time goes by, and institutions such as the Army may have no option but to adapt.

NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

A study recently asked users of psychedelic substances to share their experiences with the drugs and, in particular, their bad trips. The study, which was reported in the “International Journal of Drug Policy,” found that many users of psychedelic substances used storytelling to redefine bad trips and make them positive experiences.

Hallucinogens, or psychedelics, are psychoactive substances that activate altered states of consciousness, influencing an individual’s cognition, perception and mood. Hallucinogens are considered to be low in toxicity and aren’t addictive, but they can sometimes cause challenging trips, which are basically negative reactions that can include frightening hallucinations, panic attacks, paranoia and anxiety.

Despite having these unpleasant experiences, psychedelic users embraced the positives in bad trips, observed the researchers. Researchers included Liridona Gashi, Willy Pedersen and Sveinung Sandberg, who suggest that storytelling may be useful in helping users of psychedelics find meaning in challenging trips.

For their study, the researchers recruited 50 psychedelic users who were in their early 20s and late 30s; the teams then conducted interviews with those users. The team found that psilocybin and LSD were the most commonly used drugs, noting that most of the participants had used psychedelics less than 50 times.

During the interviews, each participant was asked questions about their experiences with bad trips, including how they felt a day after the trip, if the experience had changed them and how scared they were. In their study, the researchers noted that apart from two participants, the remaining number had experienced bad trips.

Similar to prior findings, most stories included troubling visions, panic attacks, confusion and paranoia. The researchers added that the majority of the participants also described intense feelings of losing their sense of self or going insane.

Despite these negative experiences, most participants recalled their trips with gratitude, which proposes that the experiences had unearthed feelings that had been repressed and provided them with deep insights into various matters. In addition, some participants suggested that bad trips mainly arise due to the lack of competence of the drug user.

The researchers also stated that the stories on bad trips were extremely detailed and rich, noting that the psychedelic users were adept at storytelling and had extensive vocabularies. The researchers suggest that these narratives may help explain why bad trips can be interpreted as both positive and negative experiences at the same time, adding that storytelling may play the role of a coping mechanism, assisting the individuals to draw meaning from the negative experiences and process their emotions.

The possibility of a bad trip may be the reason why a variety of companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), see psychedelics as medicinal formulations that should only be used under the watchful eye of trained medical personnel.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

• BRSF is about to enter into a merger agreement to acquire Piezo Motion, a leading piezo motor technology developer
• Piezo Motion’s technology will be deployed to leverage massive amounts of data that can be analyzed by artificial intelligence to assist medical professionals and researchers in recommending adequate precision treatments
• Merger expected to expand markets for both companies and their potential to deliver innovative technologies to high-growth segments

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced that it has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology (https://ibn.fm/WBhls). By combining aspects of physical and social sciences with machine learning, the two companies seek to better understand and address emerging commercial demands in the market. Once completed, the merger is expected to expand the market footprint both for Brain Scientific and Piezo Motion and their potential to deliver innovative technologies to high-growth markets.

The two companies leverage teams of scientists, engineers, and executives with a track record of developing and commercializing disruptive technologies. Brain Scientific’s two FDA-cleared products and commercialized devices, NeuroCap(TM) and NeuroEEG(TM) are designed to disrupt the current electroencephalogram (“EEG”) market by providing cost-effective and disposable alternatives to existing solutions, allowing medical professionals to collect diagnostic information quickly.

Piezo Motion is a leading developer of affordable piezoelectric motors and innovative piezoelectric polymer actuators and electrode components with applications in medical devices, industrial equipment, and the aerospace industry (https://ibn.fm/o0XmE). The company offers a portfolio of precision motion solutions that allow original equipment manufacturers (“OEM”) to develop energy-efficient precision products. These solutions can be deployed across various applications, including wearable drug delivery, surgical robotics, and other industrial precision applications in high-growth markets such as autonomous vehicles and aerospace.

“We are excited for the future that the merger with Piezo Motion is expected to bring. Together, we plan to achieve rapid expansion while delivering and developing the new generation of MedTech solutions for the brain diagnostics market, including innovative products for long-term monitoring and brain e-tattoo. This combination offers a significant opportunity to be part of a company well-positioned for growth. We look forward to uniting with Piezo Motion in what we expect will be an exciting new chapter ahead.”, said Dr. Baruch Goldstein, Founder of Brain Scientific.

CEO of Piezo Motion, Hassan Kotob, appears equally enthusiastic about the transaction and the impact it is expected to have on the two companies. “Brain Scientific and Piezo Motion come together with breakthrough proprietary technologies addressing fast-growing multi-billion-dollar markets in medical technology, pharmaceutical research, industrial automation, biotechnology, and more.”, he stated.

The transaction is expected to close in July 2021 and is subject to regular closing conditions, including the two company’s shareholders’ approval and the successful consummation of a minimum $5 million capital raise. Brain Scientific will acquire 100% of Piezo Motion’s outstanding shares and its assets and liabilities. Piezo Motion’s shareholders will receive a number of shares of Brain Scientific’s common stock equal to 100% of its outstanding shares immediately before closing on a fully diluted, as-converted basis. Directors of Brain Scientific, Boris Goldstein, and Nickolay Kukekov are expected to remain on the Board, with three new additions from Piezo Motion. Hassan Kotob, current CEO of Piezo Motion, will take the role of Chairman and CEO of the combined company, which will initially have offices in New York, Silicon Valley, Florida, and Europe.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Over the next few decades, electric vehicles (“EVs”) are expected to replace the petrol and diesel-powered cars that have been a staple on the roads for more than a century. Anyone who’s aware of battery electric vehicles (“BEVs”) has probably heard that they are cheaper to maintain. But how exactly does one maintain an electric car over its lifetime? And why are these maintenance costs said to be less compared to conventional vehicles? Let’s take a look.

Rather than an internal combustion engine, electric vehicles are powered by a rechargeable lithium-ion battery pack, which will require less maintenance. Compared to a conventional car, an EV has significantly fewer moving parts, around 20 to be exact, while a gasoline or diesel-powered car has a whopping 2,000, representing numerous points of possible failure. As EVs have significantly fewer moving parts, owners don’t have to visit a mechanic regularly to make sure those parts are all functioning properly.

The vehicles also don’t require oil, so owners won’t have to make the four or so annual visits to the mechanic for oil changes, saving both time and money. Consequently, EV maintenance costs will be significantly less by virtue of having fewer parts to maintain. However, EV owners will still have to keep an eye on the brakes, tires, airbags, steering and suspension, windshield wipers and fluids, and cabin air filters.

Owners will need to make sure the tires are fully inflated and check for wear and tear as needed. They will need to do the same with the windshield wiper fluid, filling it up when necessary. Every 7,500 miles or so, an EV should be taken to a certified EV mechanic to ensure its components are in good shape. The mechanic will check for fluid leaks in the battery coolant heater, power inverter, accessory power and charge modules; they will also inspect the half-shafts, driveshafts, power steering, accelerator pedal, airbag system, gas struts (suspension), and body components for any damage and make the appropriate repairs.

The battery, which is the most important part of the EV, will also require extra care to ensure it charges and discharges energy efficiently for a long time. For starters, watch out for extreme heat and cold as temperatures will affect a battery’s range and longevity. If owners are able, they should park their vehicles in garages or under shade during extreme heat and park the cars in the sun when it gets too cold.

Charging habits will also affect the battery, so owners should be sure to keep levels under 75% to 80% while not letting levels get below 15% to 20%. Additionally, it is recommended that owners use fast charging only occasionally as it can strain the battery and cause it to degrade.

If it is within an owner’s budget, it is ideal to install a Level 2 charger at home and charge the EV overnight. Trickle and timed chargers are also recommended as they can charge an EV slowly and keep the battery from wearing down too quickly. With American drivers totaling an average of 25.9 miles per day, most drivers won’t need to use a fast charger unless they are taking a long trip.

At the end of the day, an EV does still need maintenance, but generally that maintenance involves less time at the mechanic and less strain on a wallet.

Needless to say, individual sector players such as Net Element (NASDAQ: NETE) are likely to avail specific maintenance information on the models that they release onto the market, and that information can be helpful in preventing the premature aging of EVs.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

A recent study by the St. Jude Children’s Research Hospital and the School of Medicine at the Washington University in St. Louis proposes that young patients with an average risk medulloblastoma can, after a six-week radiation treatment regimen, undergo a radiation boost to a smaller area of the brain.

Medulloblastoma is a pediatric brain cancer that usually affects the spine and/or brain and can spread through a patient’s spinal fluid. The standard of care for this type of cancer includes radiation therapy to the whole spine and brain, after which an extra dose of radiation to the back of the brain is administered in order to prevent the spread of the cancer.

While this is the standard treatment, the radiation utilized in the treatment of these tumors damages cognitive function, particularly in young patients whose brains are still in the early development stages.

Researchers believe that preventive radiation treatment doses that are administered to the patient’s spine and brain over the six-week course cannot be decreased with diminishing survival. In their study, the researchers found that each patient’s cancer responded differently to treatments, noting that this was dependent on the tumors’ biology, which sets the stage for future trials of targeted therapies. The study’s findings were reported in the “Journal of Clinical Oncology.”

Patients with pediatric average risk medulloblastoma have five-year survival rates of 75–90%. Contrastingly, those suffering from high-risk medulloblastoma have five-year survival rate of 50–75%. Factors such as tumor spread and the age of a child are also considered in determining each patient’s risk category.

For their research, scientists focused on patients suffering from average-risk medulloblastoma. They evaluated more than 400 patients, between the ages of 3 and 21, who were diagnosed with the aforementioned cancer. Patients aged between 3 and 7 were randomly assigned to receive either low-dose or standard-dose radiation to the spine and head region in every treatment given over the six-week period. Patients above this age received the standard dose, as their brain development isn’t as vulnerable to radiation.

Prof. Jeff M. Michalski of radiation oncology noted that the objective of the study was to see if the amount of radiation could safely be reduced without affecting the treatment’s efficacy. The researchers discovered that while decreasing the radiation dose over the six-week treatment period negatively affected survival, it was also possible to safely decrease the volume size of the brain that received the radiation boost at the end of the treatment period. Michalski hopes that these measures may assist in the reduction of the treatment’s effects, particularly in younger patients.

Some companies, such as  CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are also working to come up with better remedies for cancers affecting the brain or central nervous system, and these novel treatments could offer superior clinical outcomes.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
• This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
• The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
• XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023

For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy.

XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary quarantine restrictions. With this test, XPhyto also promises to increase safety in schools, medical centers and other government services and facilitating rapid airport, border and cruise ship testing to minimize travel risk.

Summer is usually the high travel season. With the Covid-19 outbreak, there has been a surge in demand for reliable and rapid testing. XPhyto acknowledges this demand and plans on capitalizing on it with its Covid-ID Lab kit, the fastest PCR system in the world, according to XPhyto’s Chief Executive Officer (“CEO”), Hugh Rogers.

“Our portable Covid-ID Lab is designed to be one of the fastest PCR systems in the world, while our platform is economic at low to mid-range sample volumes,” said Hugh Rogers, the CEO and director of XPhyto. “We anticipate strong and sustainable demand for our rapid and versatile PCR system and look forward to further expanding our reach,” he added (https://ibn.fm/sgnkA).

XPhyto Therapeutics Corp. is a bioscience accelerator focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its profile currently falls under three broad categories: diagnostics, drug delivery, and drug development (https://ibn.fm/GJn0r). For drug development, XPhyto focuses on four late-stage neurology therapeutics within clinical development, along with two other psychedelic medicine programs. For its drug delivery program, XPhyto has a platform technology already in place. It is designed to develop innovative, cost-effective transdermal and oral dissolvable formulations of hybrid-generic, generic and new active pharmaceutical ingredients.

XPhyto’s diagnostics lead product is the rapid POC COVID-19 RT-PCR diagnostic test, which launched in Europe in April 2021. The goal for the entire program is to develop real-time ultra-low-cost infectious disease biosensors and making tests, particularly Covid-19 PCR tests, fast and affordable.

With the growing requirement for PCR tests for travelling, XPhyto recognizes the tremendous potential for rapid PCR checks from a commercial standpoint.

“Rapid, reliable and decentralized PCR tests are exactly what the market needs right now; precisely because incidence rates are falling and therefore sample numbers are decreasing,” noted Michael Kretzer, the CEO of Max Pharma, XPhyto’s distribution partner and pharmaceutical wholesaler (https://ibn.fm/dDOjN). “There will be areas of application where rapid, reliable, and universally recognized results are always required. Accordingly, we see a specialized and sustainable opportunity for the Covid-ID and anticipate a steep order volume uptake in the near future,” he added.

Covid-ID Lab represents a significant shift from conventional PCR testing models. Typically, samples collected are shipped to large centralized and automated labs for processing. This has been known to not only take time but also be expensive (https://ibn.fm/4RMhK). XPhyto seeks to address this with its decentralized testing model. It projects that it will yield faster results, more versatile test center options and, most importantly, cost-effectiveness at lower testing volumes.

The deployment of the 1000 Covid-ID Lab test kits marks the start of a short trial period for integrating and evaluating XPhyto’s new PCR test system. The entire process is designed so that sample processing will occur directly at the sample collection site. The data collected will allow the company to launch the product successfully in other locations across Europe.

XPhyto continues to innovate and grow its three key sectors. With the deployment of its Covid-ID Lab, the company aims at capitalizing on the rapid test market that is projected to reach $39.1 billion by 2023, representing a compound annual growth rate (“CAGR”) of 8.9% between 2021 and 2023. The two other aspects of XPhyto’s diagnostic pipeline include the Peptide biosensor for infectious diseases and the Peptide biosensor for oral health, both of which are still in their design and development stages.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

After more than a century of dominating the roads, internal combustion engines (“ICE”) seem to be on the way out. ICE vehicles, especially passenger vehicles, are responsible for close to 30% of global carbon emissions. As climate change accelerates and the planet heats up, zero-emission electric vehicles (“EVs”) have been crowned the successor of the internal combustion engine.

However, EVs still make a small percentage of global vehicle sales, a paltry 4% to be exact, with most drivers opting for tried and tested petrol and diesel-powered cars. They can take hours to fully charge, and an insufficient and often unreliable network of public charging stations has kept plenty of drivers from switching to electric vehicles. Fast-charging technology is one of the best ways to allay range anxiety, and a new ultra-fast charger from Nidec Industrial Solutions may be what the industry needs to supercharge EV adoption.

Nidec Industrial Solutions has installed an ultra-fast charging station on an Italian state highway that is capable of supplying up to 320 kW of power to a single vehicle. In addition, it can be connected to both MV and LV grids. Consequently, it can charge electric vehicles to 80% in less than 15 minutes. Additionally, it does so without placing a significant strain on the electricity grid, which will have to be beefed up in the coming years to support a mass shift to electric cars.

Installed along Telesina state highway 372, the ultra-fast charging station, which features the most advanced, new-generation, ultra-fast chargers in the market, will be a godsend for drivers taking long trips using that route. Due to its compact size, the new ultra-fast charging system can be distributed to other regions to meet the demand for fast-charging infrastructure. Were other countries to adopt such ultra-fast charging technology, they would be able to develop a widespread network of fast chargers, eliminating one of the main obstacles to mass EV adoption.

Range anxiety has been a major hindrance to electric vehicle adoption in most cities and countries. Although most drivers generally drive an average of 25 miles a day, they would still prefer a vehicle that can allow them to take longer trips without any anxiety. Installing ultra-fast charging stations such as Nidec’s along highways would not only ease drivers’ fears of running out of power without a charging station in sight, but it would also allow those drivers to recharge their vehicles in a relatively short time and be on their way.

To avoid straining the national grid too much and forcing energy providers to use more fossil fuels to generate electricity, Nidec’s ultra-fast charging stations employ battery energy storage.

Moving forward, developing a network of ultra-fast charging stations that can charge numerous types of vehicles, from passenger cars and buses to commercial vehicles, using mostly clean energy could be one of the only ways to increase EV adoption. For-profit companies such as Ideanomics Inc. (NASDAQ: IDEX) have realized this need and are providing wireless charging facilities geared at commercial vehicles. This will increase EV adoption in this market segment and the industry in general.

NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• HempFusion Wellness closed the acquisition of Sagely Naturals, a women-centric CBD company, for an initial consideration of US$25 million in cash and stock payments
• The acquisition is expected to benefit both parties in various ways, including by increasing HempFusion’s revenue and providing access to Sagely’s extensive distribution footprint
• On its part, Sagely will benefit from HempFusion’s regulatory compliance, which will help in the introduction of ingestible CBD products
• HempFusion is looking forward to driving shareholder value through continued growth both domestically and internationally with its expanding family of brands

In fulfillment of a merger agreement announced in late May, Denver-based leading health and wellness company HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 800) completed the acquisition of premier women-centric CBD brand Sagely Enterprises Inc. (“Sagely Naturals”) on July 7 (https://cnw.fm/86bVZ). The purchase, which made Sagely Naturals a wholly owned subsidiary of HempFusion Wellness, is expected to benefit both parties.

Boasting an extensive retail distribution footprint of 14,000+ stores in the United States, Sagely Naturals is the third most successful brand, leading CBD topicals brand, and largest women-founded CBD company in the industry. This market position is reflected in its financials for the fiscal year 2020, in which it reported net revenue of over $4.19 million.

The now wholly owned subsidiary provides HempFusion with immediate distribution to up to 14,000 additional stores as well as a significant increase in revenue. In fact, when combined with the closing of APCNA Holdings LLC’s (“Apothecanna”) purchase agreement, announced May 17, HempFusion’s 2020 revenue will more than triple. Both acquisitions further offer the opportunity to expand this revenue well into the future.

In an interview with Proactive (https://cnw.fm/SZCRE), HempFusion CEO Jason Mitchell, N.D., noted that while Sagely Naturals does not offer ingestible CBD products at the moment, HempFusion’s focus on being regulatorily compliant will allow it to install a completely new ingestible program for them. This will provide an opportunity to introduce ingestible CBD products in up to 14,000 stores. “So, we are going to give them near-immediate expansion into new products they haven’t had previously,” said Mitchell.

HempFusion’s significant investment into regulatory compliance will help solidify Sagely Natural’s leadership position in the CBD industry. HempFusion has also included Sagely Naturals on its Novel Foods Application Dossier with the United Kingdom’s Regulatory Food Safety Agency to aid in future expansion into Europe.

Additionally, as both companies have complementary product offerings that do not directly compete, the acquisition offers substantial cross-platform opportunities through each of their respective distribution channels.

“Integration has been well underway over the past several weeks, and we look forward to driving shareholder value through continued growth in 2021 and 2022 both domestically and internationally with our expanding family of brands,” stated Mitchell in a press release.

HempFusion closed the acquisition for an initial consideration of US$25 million, of which $2 million was paid in cash (subject to adjustment for Sagely Naturals’ cash and working capital), and the balance was satisfied by the issuance of more than 22.5 million common HempFusion shares. You can find a comprehensive description of the terms of the acquisition in the press release.

In the Proactive interview, Mitchell held that M&A remains a vital part of the company’s future. Thus, the recent acquisition of Sagely Naturals “is certainly not going to be our last.”

For more information, visit the company’s website at www.HempFusion.com/corporate-information.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://cnw.fm/CBDHF

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

New research conducted by a group of scientists from Finland and the UK, led by a team from University of Birmingham, has found that children who experience cognitive difficulties such as a lack of inhibition, poor memory or low attention may suffer from mental health problems as young adults or teenagers.

On a global scale, mental disorders affect about 10% of adolescents and children, with researchers finding that 75% of the disorders diagnosed in adulthood usually begin during adolescence or childhood. For instance, disorders such as psychosis, depression and bipolar disorder often emerge during adolescence and continue into adulthood.

The researchers note in their study, which was reported in “JAMA Network Open,” that targeting certain markers in childhood for early treatment may assist in reducing the risk of the children developing psychopathological issues such as psychosis, depression and borderline personality disorder in their adult lives or during adolescence.

The study explains that cognitive deficits are key features of mental disorders and can help predict long-term prognosis.

For their study, the researchers examined data from a preliminary UK cohort made up of more than 13,000 individuals who had been born April 1991 through December 1992, which led to the discovery of associations between mental health problems in later life and childhood cognitive issues.

For instance, the researchers found that:

• Memory deficits in 10-year-olds were linked to hypomania at ages 22 to 23
• Shortfalls in attention in 8-year-olds paved the way for the development of depression at 17 or 18 years of age as well as borderline personality disorder symptoms at 11 and 12 years

Prior studies have provided evidence proposing a link between symptoms of childhood attention deficit hyperactivity disorder and adult borderline personality disorder, which implies that ADHD may be a risk factor for borderline personality disorder.

Dr. Isabel Morales-Muñoz from the Finnish Institute for Mental Health and the Mental Health Institute at the University of Birmingham stated that the study underlined the potential effect of childhood cognitive deficits on young individual’s mental health, proposing certain links with specific conditions. Morales- Muñoz, who was also the study’s lead author, then added that prevention strategies that centered on reducing these issues could help decrease the risk of the children developing associated mental health issues in early adulthood and during adolescence.

This research also backs the theory that difficulties with inhibition in childhood sets the scene for psychotic disorders like schizophrenia.

Steven Marwaha, Matthew R. Broome, Pavan K. Mallikarjun and Rachel Upthegrove were also members of the research team for this study.

It is of concern that childhood cognitive issues can develop into mental health problems later in life, but the silver lining in this cloud is many companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), are working to revolutionize the way in which mental health conditions are treated, which could bring lasting results to patients.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

A recent study has found that drivers who consume marijuana may not perform or feel impaired. The study found that, instead, drivers who used marijuana would sometimes experience a positive effect on their driving.

This comes at a time when policy makers are working to decide whether driving while under the influence of marijuana warrants similar penalties to driving while under the influence of alcohol in various states across the country. Under the law, impairment is defined as a state of diminished or weakened function.

In many states, the legal limit for blood–alcohol content is 0.08. It is known that a driver who has been awake for more than 20 hours drives with the same impairment level as an individual with the aforementioned blood-alcohol content. However, the stance on marijuana impairment keeps shifting because while it is known that the plant does cause impairment, establishing an acceptable limit seems to be a challenge.

The fact that marijuana metabolites also remain in the human saliva or blood long after the plant’s effects have worn off is also a challenge as it makes it harder for cannabis breathalyzer tests to conclusively measure the impairment level of a driver who’s been using cannabis.

Despite this, some states, including Colorado, have still imposed limits on the level of THC metabolites that can be found in a driver’s blood.

The study, which was conducted by University of Iowa researchers, found that marijuana compounds that give rise to other effects, apart from being high, could probably help individuals drive a bit better. The study, which was reported in the “Traffic Injury Prevention” journal, involved 10 drivers who were each evaluated on their road abilities two hours after they had  consumed marijuana.

Each driver was asked to rate their perceived level of impairment before they performed some simulated tasks. Prior research had discovered that drivers who were stoned took fewer risks and were more aware of their impairment when compared to drivers who were inebriated and took more risks.

The authors of the study explained that with regard to longitudinal and lateral control, a growing perception of stimulation gave rise to a positive effect on the drivers’ performance. They added that the study results offered a better understanding of how various strains of marijuana, which gave rise to different experiences for users, could affect driving safety.

The researchers also noted that drug effects that produced more high or stoned feelings resulted in a greater negative impact on driving while those that caused more stimulation had a lesser effect on driving. This isn’t to mean that driving after consuming marijuana is safe, it just means that the level of impairment may not be as pronounced, depending on the marijuana strain consumed.

This study highlights why companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) have invested immensely in studying the specific effects of various cannabinoids so that they can develop therapeutic formulations to treat a variety of conditions.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://cnw.fm/XPHYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Cannabis and cannabis extracts are becoming more popular as more states across the country legalize the plant for recreational and/or medical use. CBD, or cannabidiol, is a chemical compound that is extracted from the cannabis sativa plant. The compound can be consumed through edible consumption or smoke inhalation, in addition to being applied topically. It interacts with neuro-receptors in an individual’s endocannabinoid system, which send signals between the body’s cells to help regulate the immune system, homeostasis, mood and movement.

Cannabidiol is usually extracted in oil form and has recently become popular because of its calming effects. Below are a few ways CBD oil can benefit health and wellness, as suggested by preliminary research on the compound.

Protect against neurological ailments

Clinical and preclinical studies have found that CBD possesses anti-inflammatory and antioxidant properties that could offer considerable protection against various pathological disorders. Some preclinical studies also propose that the compound produces beneficial effects against multiple sclerosis, Alzheimer’s disease and Parkinson’ disease.

Alleviate pain

Studies conducted in the United States indicate that CBD is efficacious in treating chronic pain when administered topically. Research results from a 2020 study show that the use of topical CBD in managing pain in patients with symptomatic peripheral neuropathy resulted in considerable reductions in intense sharp pains.

Reduce symptoms of ALS

Amyotrophic lateral sclerosis (“ALS”) is an ailment that causes nerve cells in an individual’s spinal cord and brain to deteriorate, which brings about loss in muscle control. The disease has no cure, and only two medications exist that are approved by the FDA for the management of this condition. A 2019 study suggests that ALS patients can benefit from a combined CBD and THC treatment, with patients who suffered from mild-to-severe muscle stiffness and tightness reporting high levels of satisfaction.

Decrease symptoms of post-traumatic stress disorder

A 2018 study that involved 11 individuals who all suffer from PTSD found that the use of CBD in conjunction with psychiatric care decreased the patients’ symptoms. Other studies on the same topic have found that CBD used together with THC enhances the former’s effects in reducing symptoms of PTSD.

Neutralize anxiety

Numerous studies on the use of cannabis and its extracts in helping combat anxiety have been conducted in the recent past. A study conducted in 2017 found that CBD was effective in reducing anxiety when used in moderate doses.

The above are only a few of the ways in which CBD can be provide health benefits. Researchers are focused on finding out more about this compound and any additional benefits that it may possess.

Many companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are marketing a variety of CBD-infused products. It is good to learn that scientific studies are revealing some of the benefits that consumers could derive from using these widely available products.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.